Skip to content

Palisade Bio Inc PALI Stock Analysis

  • Nasdaq
  • Stock
  • Market closed · opens Monday 9:30 AM ET

$1.12 down $0.02, 1.75% at close Nov 13

Last close · Previous close $1.14

Unverified per-share results and the ratios based on them are paused while we verify that Tiingo’s statements reflect the Apr 8 stock split. Each statement period is checked separately; refreshing statements alone does not verify their split basis. How earnings per share work

Market cap
At the Nov 13 close
P/E ratio
1.23On last 12 months’ EPS
Diluted EPS
$0.91Last 12 months
Dividend yield
NoneLast 12 months

Price chart

$1.12down $0.02, 1.75%Fri, Nov 13 session

Use the left and right arrow keys to move along the chart.

Chart period
IEX trades, regular session · Times in ET
Price data

Trading

At last close

  • Previous close$1.14Nov 12
  • Volume1.46MNov 13 session
  • Avg. volume3.75MLast 21 sessions
  • 52-week range: $1.08 to $2.86; now $1.12
Member SIPC.Low CommissionsLearn More (opens in a new tab)

Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.

Performance

Past performance, measured to the Nov 13 close. Total return includes reinvested dividends. Compared with the S&P 500, using SPY.

Return type

PALI trailed the S&P 500 in all 7 periods.

PALI total returns compared with the S&P 500
PeriodPALI and S&P 500vs S&P 500
Short term
1M
PALI: down 23.5%
S&P 500: down 3.0%
PALI trailed the S&P 500 by 20.5 percentage points
3M
PALI: down 47.9%
S&P 500: down 2.8%
PALI trailed the S&P 500 by 45.1 percentage points
YTD
PALI: down 52.3%
S&P 500: up 11.5%
PALI trailed the S&P 500 by 63.8 percentage points
1Y
PALI: down 40.1%
S&P 500: up 13.5%
PALI trailed the S&P 500 by 53.6 percentage points
Long term
3Y
PALI: down 85.8%
S&P 500: up 77.7%
−47.9% vs +21.1% a year
PALI trailed the S&P 500 by 163.5 percentage points
5Y
PALI: down 99.9%
S&P 500: up 72.6%
−77.6% vs +11.5% a year
PALI trailed the S&P 500 by 172.5 percentage points
10Y
PALI: down 100.0%
S&P 500: up 308.4%
−71.6% vs +15.1% a year
PALI trailed the S&P 500 by 408.4 percentage points

$10,000 invested in PALI 10 years ago (Nov 11, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $40,844.

All-time high

$5,452,200.00

Closing high on . Now 100.0% below that record.

Split-adjusted daily closes since Dec 20, 2006.

Stock splits

5

Latest: 1-for-15 on . Share counts adjust after each split.

All 5 splits
  • 1-for-15
  • 1-for-50
  • 1-for-6
  • 1-for-20
  • 1-for-13

Valuation

Financials

Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.

Chart periods

Revenue and net income

Last 12 months, with the change from the 12 months before

Revenue
$500.00K
Net income
−$43.70M
Diluted EPS
$0.91
Last 8 fiscal quarters
Data table
PALI quarterly results
PeriodRevenueNet incomeDiluted EPS
Q4 FY24 (Dec 31, 2024)$0.00−$3.34M−$0.69
Q1 FY25 (Mar 31, 2025)$0.00−$2.23M−$0.47
Q2 FY25 (Jun 30, 2025)$0.00−$2.78M−$0.58
Q3 FY25 (Sep 30, 2025)$0.00−$2.87M−$0.38
Q4 FY25 (Dec 31, 2025)$0.00−$8.90M$1.08
Q1 FY26 (Mar 31, 2026)$0.00−$9.60M−$0.05
Q2 FY26 (Jun 30, 2026)$500.00K−$10.57M−$0.05
Q3 FY26 (Sep 30, 2026)$0.00−$14.62M−$0.07

Margins

  • Gross 100.0%
  • Operating −9,625.4%
  • Net −8,739.2%

The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you

Cash flow

  • −$26.40MLast 12 months
  • Operating cash flow−$26.40MLast 12 months
  • Capital spending$0.00Last 12 months
  • −5,279.2%Last 12 months

Shareholder returns

  • $135.07MLast 12 months
  • Dividends paid$0.00Last 12 months
  • Total returned$0.00Last 12 months

Balance sheet

  • $113.67MAs of Sep 30, 2026
  • Total debt$0.00As of Sep 30, 2026
  • Net cash$113.67MAs of Sep 30, 2026
  • 20.16As of Sep 30, 2026
  • 0.00As of Sep 30, 2026

Financial strength

  • −35.6%Last 12 months
  • −34.0%Last 12 months

About Palisade Bio Inc

Palisade Bio is a late-stage biopharmaceutical company advancing oral therapies that aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s lead clinical asset LB1148 is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from completed Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Maryland, USA
Exchange
Nasdaq
Asset type
Common stock
Price history since

PALI news

PALI stock FAQ

What is PALI stock’s price today?

Palisade Bio (PALI) traded at $1.12 at the close on , down $0.02 (1.75%) from the previous close of $1.14. Over the past 52 weeks it has traded between $1.08 and $2.86.

If you invested $1,000 in PALI 10 years ago, how much would you have now?

With dividends reinvested, $1,000 invested in PALI on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $1 if invested five years ago and $599 if invested one year ago. Past performance doesn’t predict future returns.

What is PALI’s P/E ratio?

PALI trades at 1.2 times its diluted earnings over the four quarters to ($0.91 per share), at the close. (How the P/E ratio works.)

How much revenue does Palisade Bio make?

Palisade Bio reported $500.0 thousand of revenue over the four quarters to . In its latest quarter (Q3 FY26, ended ) revenue was $0.0 thousand.

Is Palisade Bio profitable?

Not over the four quarters to . Palisade Bio reported a net loss of $43.7 million across those four quarters on $500.0 thousand of revenue.

What are PALI’s earnings per share?

PALI’s diluted earnings per share were $0.91 over the four quarters to , compared with −$2.12 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.07 per share, against −$0.38 a year earlier (how EPS works).

Does PALI pay a dividend?

Palisade Bio hasn’t paid a dividend in the last twelve months.

What is PALI’s 52-week high and low?

Over the past 52 weeks PALI has traded as low as $1.08 and as high as $2.86. At $1.12 at the close on , it is 60.8% below that high and 3.7% above the low.

What is PALI’s all-time high?

PALI’s highest closing price was $5,452,200.00 on , adjusted for stock splits. At $1.12 at the close on , it is 100.0% below that record.

Has PALI stock ever split?

Yes, five times: 1-for-13 on ; 1-for-20 on ; 1-for-6 on ; 1-for-50 on ; 1-for-15 on .

How has PALI stock performed?

Including dividends and measured to the close on , PALI has returned −52.3% so far this year and −40.1% over the past year, and −99.9% over five years (−77.6% a year). Over the same periods the S&P 500, measured by SPY, returned +11.5%, +13.5% and +72.6%. Past performance doesn’t predict future returns.

What sector and industry is Palisade Bio in?

Palisade Bio is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.

What exchange does PALI trade on?

Palisade Bio trades on the Nasdaq under the ticker symbol PALI. Its price history on this dashboard begins on .

Member SIPC.Low CommissionsLearn More (opens in a new tab)

Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.

About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.

This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).

The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.

Search
Contact Ryan

Get in touch

Contact Me

Have a question or want to work together? Fill out the form below and we'll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Results appear as you type. Use the arrow keys to move through them.